A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic

BACKGROUND: Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either unknown or understudied; specifically, its usefulness in β-thalassaemia major an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasara, Nirmani, Premawardhena, Anuja, Mettananda, Sachith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919989/
https://www.ncbi.nlm.nih.gov/pubmed/33648529
http://dx.doi.org/10.1186/s13023-021-01757-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919989/
https://www.ncbi.nlm.nih.gov/pubmed/33648529
http://dx.doi.org/10.1186/s13023-021-01757-w

Ejemplares similares